Get Started

ABBV

AbbVie (ABBV)

AbbVie Inc

Date:

Regulatory News

Text Search:

Sort by:

Non-Regulatory News

Showing the most relevant articles for your search:NYSE:ABBV

<< Previous 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 Next >>

Date	Time	Source	Headline	Symbol	Company
01/25/2021	12:44PM	Dow Jones News	AbbVie: European Commission Approves Rinvoq to Treat Active Psoriatic Arthritis	NYSE:ABBV	AbbVie Inc
01/25/2021	11:30AM	PR Newswire (US)	European Commission Approves AbbVie's RINVOQ™ (Upadacitinib) for the Treatment of Psoriatic Arthritis and Ankylosing Spondy...	NYSE:ABBV	AbbVie Inc
01/25/2021	8:30AM	GlobeNewswire Inc.	Alector Announces First Participant Dosed in Phase 2 Study Evaluating AL002 in Individuals with Early Alzheimer’s Disease	NYSE:ABBV	AbbVie Inc
01/15/2021	9:00AM	PR Newswire (US)	Allergan Aesthetics and Allergan, an AbbVie Company, to Present 16 Neurotoxin Research Abstracts Across Multiple Therapeutic ...	NYSE:ABBV	AbbVie Inc
01/13/2021	7:30AM	GlobeNewswire Inc.	Harpoon Therapeutics Granted Orphan Drug Designation from FDA for HPN217 for Treatment of Multiple Myeloma	NYSE:ABBV	AbbVie Inc
01/12/2021	4:32PM	Edgar (US Regulatory)	Current Report Filing (8-k)	NYSE:ABBV	AbbVie Inc
01/12/2021	4:05PM	PR Newswire (US)	Allergan Aesthetics Enters Into Option to Acquire Cypris Medical	NYSE:ABBV	AbbVie Inc
01/12/2021	12:35PM	PR Newswire (Canada)	Dragonfly Therapeutics annonce l'option d'adhésion exercée par AbbVie concernant le médicament candidat d'immunothérapie ...	NYSE:ABBV	AbbVie Inc
01/12/2021	8:00AM	PR Newswire (US)	AbbVie to Host Fourth-Quarter and Full-Year 2020 Earnings Conference Call	NYSE:ABBV	AbbVie Inc
01/12/2021	6:45AM	PR Newswire (US)	Dragonfly Therapeutics Announces AbbVie Opt-In of TriNKET™ Immunotherapy Drug Candidate	NYSE:ABBV	AbbVie Inc
01/12/2021	6:45AM	PR Newswire (Canada)	Dragonfly Therapeutics Announces AbbVie Opt-In of TriNKET™ Immunotherapy Drug Candidate	NYSE:ABBV	AbbVie Inc
01/12/2021	6:45AM	PR Newswire (US)	Dragonfly Therapeutics Announces AbbVie Opt-In of TriNKET™ Immunotherapy Drug Candidate	NYSE:ABBV	AbbVie Inc
01/07/2021	9:56AM	Dow Jones News	AbbVie: Skyrizi Phase 3 Crohn's Induction Studies Meet Main Endpoints	NYSE:ABBV	AbbVie Inc
01/07/2021	8:45AM	PR Newswire (US)	Risankizumab (SKYRIZI®) Demonstrates Significant Improvements in Clinical Remission and Endoscopic Response in Two Phase 3 I...	NYSE:ABBV	AbbVie Inc
01/06/2021	5:01PM	Edgar (US Regulatory)	Current Report Filing (8-k)	NYSE:ABBV	AbbVie Inc
01/06/2021	8:00AM	PR Newswire (US)	AbbVie to Present at the 39th Annual J.P. Morgan Healthcare Conference	NYSE:ABBV	AbbVie Inc
01/05/2021	5:03PM	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NYSE:ABBV	AbbVie Inc
01/05/2021	5:03PM	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NYSE:ABBV	AbbVie Inc
01/05/2021	5:02PM	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NYSE:ABBV	AbbVie Inc
01/05/2021	5:02PM	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NYSE:ABBV	AbbVie Inc
01/05/2021	10:14AM	Dow Jones News	AbbVie Reports Positive Phase 3 Results of Skyrizi in Psoriatic Arthritis	NYSE:ABBV	AbbVie Inc
01/05/2021	8:48AM	PR Newswire (US)	Risankizumab (SKYRIZI®) Phase 3 Results Demonstrate Improvements in Disease Activity Across Joint and Skin Symptoms Among Ps...	NYSE:ABBV	AbbVie Inc
12/31/2020	1:16PM	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NYSE:ABBV	AbbVie Inc
12/31/2020	1:15PM	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NYSE:ABBV	AbbVie Inc
12/31/2020	1:14PM	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NYSE:ABBV	AbbVie Inc
12/23/2020	7:30AM	PR Newswire (US)	IMBRUVICA® (ibrutinib) U.S. Prescribing Information Updated to Include Long-Term Data for Waldenström's Macroglobulinemia (...	NYSE:ABBV	AbbVie Inc
12/16/2020	7:09PM	Dow Jones News	US ITC Blocks Imports of Jeuveau Wrinkle Treatment -- Bloomberg	NYSE:ABBV	AbbVie Inc
12/15/2020	7:30AM	PR Newswire (Canada)	Santé Canada approuve l'indication de VENCLEXTA® (vénétoclax) en association avec l'azacitidine ou avec la cytarabine à ...	NYSE:ABBV	AbbVie Inc
12/15/2020	7:30AM	PR Newswire (Canada)	Health Canada Approves VENCLEXTA® (venetoclax) in combination with azacitidine or low dose cytarabine for untreated Acute My...	NYSE:ABBV	AbbVie Inc
12/11/2020	4:35PM	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NYSE:ABBV	AbbVie Inc